Wall Street analysts expect Evelo Biosciences, Inc. (NASDAQ:EVLO) to report ($0.53) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Evelo Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.60) and the highest estimate coming in at ($0.45). Evelo Biosciences reported earnings of ($0.45) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 17.8%. The firm is scheduled to announce its next quarterly earnings results on Thursday, November 4th.
On average, analysts expect that Evelo Biosciences will report full year earnings of ($2.24) per share for the current financial year, with EPS estimates ranging from ($2.27) to ($2.20). For the next financial year, analysts anticipate that the company will post earnings of ($2.01) per share, with EPS estimates ranging from ($2.20) to ($1.91). Zacks’ earnings per share averages are a mean average based on a survey of research firms that follow Evelo Biosciences.
Evelo Biosciences (NASDAQ:EVLO) last issued its earnings results on Wednesday, July 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.54) by $0.01.
Shares of EVLO stock traded up $0.21 during trading hours on Wednesday, hitting $6.99. The company’s stock had a trading volume of 30,320 shares, compared to its average volume of 217,665. The business has a fifty day moving average of $10.28 and a 200-day moving average of $11.66. The stock has a market cap of $373.25 million, a price-to-earnings ratio of -3.36 and a beta of 1.29. Evelo Biosciences has a twelve month low of $3.82 and a twelve month high of $19.93. The company has a current ratio of 6.38, a quick ratio of 6.38 and a debt-to-equity ratio of 0.75.
Several institutional investors and hedge funds have recently made changes to their positions in EVLO. Meeder Asset Management Inc. purchased a new position in shares of Evelo Biosciences in the 1st quarter valued at $28,000. Metropolitan Life Insurance Co NY purchased a new stake in Evelo Biosciences during the 2nd quarter worth $123,000. Cresset Asset Management LLC purchased a new stake in Evelo Biosciences during the 2nd quarter worth $137,000. OLD Mission Capital LLC purchased a new stake in Evelo Biosciences during the 2nd quarter worth $138,000. Finally, American International Group Inc. grew its holdings in Evelo Biosciences by 15.5% during the 1st quarter. American International Group Inc. now owns 13,422 shares of the company’s stock worth $144,000 after acquiring an additional 1,801 shares in the last quarter. Institutional investors own 85.44% of the company’s stock.
Evelo Biosciences Company Profile
Evelo Biosciences, Inc operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. Its portfolio includes EDP1066 and EDP1815 for the treatment of inflammatory diseases; EDP2939 for inflammation; and EDP1908 for oncology. The company was founded by Noubar B.
Recommended Story: What is the S&P/ASX 200 Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.